Table 3 EGFR tyrosine kinase inhibitors or mono-clonal antibodies combined with radiotherapy

TKI

Okamoto et al [55]

Gefitinib x 14 days, then given concurrently with RT

III

9

60 Gy

4 pts who completed with PR

2 pts with EGFR mutations lived >5 yrs.

Choong et al [56]

Erlotinib + Cisplatin + Etoposide + RT then docetaxel x 3 cycles vs. Carboplatin + Paclitaxel , then Erlotinib + Carboplatin + Paclitaxel + RT

III

17 vs. 17

66 Gy

65% vs. 59%, p = ns

13% vs. 15% at 3 yrs, p = 0.9168

11 mo vs. 15 mo, p = 0.8979

Rothschild et al [57]

Erlotinib + RT or Erlotinib + Cisplatin + RT

III

14

63 Gy

21.4%

6.0 mo

12.7 mo

Wang et al [58]

Gefitinib or Erlotinib + RT

III/IV

26

70 Gy

96%

10.2 mo

21.8 mo

Center et al [59]

Gefitinib + Docetaxel + RT

III

16

70 Gy

7.1 mo

21.0 mo

Stinchcombe et al [60]

Carboplatin + Irinotecan + Taxol followed by Carboplatin/Taxol + Gefitinib + RT

III

23

74 Gy

24%

9 mo

16 mo

Ready et al [61]

Carboplatin/Taxol x 2 cycles ± Gefitinib then Gefinitib + RT vs. Carboplatin/Taxol + Gefitinib + RT; both groups are given Gefitinib after RT if w/o severe radiation toxicity.

III

21 vs. 39

66 Gy

52.40% vs. 81.60%, p = 0.034

13.4 mo vs. 9.2 mo

19.0 mo vs. 13.0 mo

Chang et al [62]

Upfront TKI, followed by TKI + multitarget IMRT with helical tomotherapy

IIIB-IV

25

40-50 Gy in 16–20 daily fractions.

84%

16 mo

Not reached, 3 yr OS 62.5%

Komaki et al [63]

Carboplatin + Paclitaxel on Monday, followed by Erlotinib for the rest of the week combined with RT; Consolidative Carboplatin + Paclitaxel x 2 cycles were then given

III

46

63 Gy/ 35 daily fractions

80%

14.5 mo

34.1 mo

Cetuximab or Nimotuzumab

Hughes et al [66]

Platinum based chemotherapy followed by Cetuximab + RT

III-IV

12

64 Gy

70%

Choi et al [67]

Weekly Nimotuzumab + RT, then q2 weeks till progression

IIB-IV

15

30 or 36 Gy in 3 Gy fractions

46.70%

5.4 mo

9.8 mo

Bebb et al [68]

Weekly Nimotuzumab + RT, then q2 weeks till progression

III-IV

18

30 or 36 Gy in 3 Gy fractions

66%

4 mo

15 mo

Govindan et al [69]

Carboplatin + Pemetrexed + RT vs. Carboplatin + Pemetrexed + Cetuximab + RT

III

48 vs. 53

70 Gy

77% vs. 72%, p = ns

12.6 mo vs. 12.3 mo, p = ns

21.2 mo vs. 25.2 mo, p = ns

Jensen et al [70]

Cetuximab + RT followed by maintemance Cetuximab

III

30

66 Gy

8.5 mo

19.6 mo

Hallqvist et al [71]

Cisplatin + Docetaxel followed by Cetuximab + RT

III

75

68 Gy

23.5%

17 mo

Blumenschein et al [72]

Carboplatin + Taxol + Cetuximab + RT followed Carboplatin + Taxol + Cetuximab

III

87

63 Gy

62%

12 mo

22.7 mo